search
Back to results

Ethanol Sclerotherapy Prior to ART (START)

Primary Purpose

Endometrioma, Infertility, Sclerotherapy

Status
Recruiting
Phase
Not Applicable
Locations
Turkey
Study Type
Interventional
Intervention
Ethanol Sclerotherapy for Endometrioma
Sponsored by
Ankara University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Endometrioma focused on measuring endometrioma, ethanol sclerotherapy, assisted reproductive technology, in vitro fertilization, cumulative live birth rate

Eligibility Criteria

18 Years - 40 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria: AMH>0.3 ng/ml unilateral/bilateral endometrioma Endometrioma diameter 40-100 mm Exclusion Criteria: 3 or more IVF/embryo transfer failure Menstrual cycle abnormalities Male Factor infertility Presence of uterine fibroids Presence of hydrosalpinx Presence of uterine abnormalities Suspicion of malignancy according to International Ovarian Tumor Analysis criteria

Sites / Locations

  • Ankara University School of Medicine, Department of Obstetrics and GynecologyRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

Control

Ethanol sclerotherapy

Arm Description

In eligible patients allocated to control group, no interventions will be done before ART cycle.

In eligible patients allocated to study group, endometrioma/s will be aspirated and treated with ethanol for 10 minutes 1-2 cycles before ART.

Outcomes

Primary Outcome Measures

Cumulative live birth rate
live births following fresh and frozen-thaw transfer of all embryos unless pregnancy occurs

Secondary Outcome Measures

pain scores
Visual Analog Pain Scale scores related to dysmenorrhea, dyspareunia, and/or pelvic pain will be measured before and after procedure

Full Information

First Posted
July 19, 2023
Last Updated
July 19, 2023
Sponsor
Ankara University
Collaborators
Hacettepe University
search

1. Study Identification

Unique Protocol Identification Number
NCT05962775
Brief Title
Ethanol Sclerotherapy Prior to ART
Acronym
START
Official Title
The Impact of Ethanol Sclerotherapy Before ART (Assisted Reproductive Technology) Cycle on Cumulative Live Birth Rate in Infertile Women With Endometrioma: A Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 1, 2023 (Actual)
Primary Completion Date
January 1, 2025 (Anticipated)
Study Completion Date
April 1, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Ankara University
Collaborators
Hacettepe University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The goal of this randomized controlled trial is to assess the impact of ethanol sclerotherapy on ART cycle outcomes. The main questions it aims to answer are: Does ethanol sclerotherapy before ART cycle has any impact on cumulative live birth rate in patients with endometrioma? Does ethanol sclerotherapy improve chronic pelvic pain, dysmenorrhea, complications during oocyte retrieval, response to ovarian stimulation (number of mature oocytes retrieved), and pregnancy loss rates? Infertile patients with endometrioma between 4-10 cm who are scheduled for ART within 2 cycles will be randomized to ethanol sclerotherapy or no intervention.
Detailed Description
The effect of ethanol sclerotherapy before assisted reproductive technology (ART) cycle in patients with endometrioma on reproductive outcomes will be investigated. While endometrioma may result in technical difficulties in the ART process, the superiority of ethanol sclerotherapy has yet to be examined before the ART procedure in randomized controlled studies and meta-analyses. The negative effect of ethanol sclerotherapy on ovarian reserve was found to be less than other existing interventions such as cyst stripping. However, randomized controlled studies did not determine its direct effect on ART outcome. Our current study aimed to assess the effect of ethanol sclerotherapy on ART outcomes. Infertile patients aged 18-40 years with at least one endometrioma 4-10 cm and scheduled for ART will be included in the study. Patients with any untreated thyroid dysfunction or additional disease, such as hyperprolactinemia, those who did not accept the study information and consent, and patients younger than 18 or older than 40 will not be included. Those who underwent surgery for endometrioma within 3 months before ART will be excluded. In addition, patients with an anti-mullerian hormone value below 0.3 ng/ml will not be included in the study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Endometrioma, Infertility, Sclerotherapy, ART, IVF
Keywords
endometrioma, ethanol sclerotherapy, assisted reproductive technology, in vitro fertilization, cumulative live birth rate

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
84 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Control
Arm Type
No Intervention
Arm Description
In eligible patients allocated to control group, no interventions will be done before ART cycle.
Arm Title
Ethanol sclerotherapy
Arm Type
Experimental
Arm Description
In eligible patients allocated to study group, endometrioma/s will be aspirated and treated with ethanol for 10 minutes 1-2 cycles before ART.
Intervention Type
Procedure
Intervention Name(s)
Ethanol Sclerotherapy for Endometrioma
Intervention Description
2 gr IV cefazolin sodium will be administered 30 minutes before the procedure. The endometrioma cyst content will be aspirated by a single lumen needle, and the total aspirated volume calculation will be done. The endometrioma will then be washed with saline until the color of the cyst content becomes clear. Then, 96% ethanol will be injected into the cyst. The volume of injected ethanol will be 60% of the first aspirated volume (maximum 100 ml). After 10 minutes all ethanol will be aspirated.
Primary Outcome Measure Information:
Title
Cumulative live birth rate
Description
live births following fresh and frozen-thaw transfer of all embryos unless pregnancy occurs
Time Frame
18 months
Secondary Outcome Measure Information:
Title
pain scores
Description
Visual Analog Pain Scale scores related to dysmenorrhea, dyspareunia, and/or pelvic pain will be measured before and after procedure
Time Frame
3 months

10. Eligibility

Sex
Female
Gender Based
Yes
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: AMH>0.3 ng/ml unilateral/bilateral endometrioma Endometrioma diameter 40-100 mm Exclusion Criteria: 3 or more IVF/embryo transfer failure Menstrual cycle abnormalities Male Factor infertility Presence of uterine fibroids Presence of hydrosalpinx Presence of uterine abnormalities Suspicion of malignancy according to International Ovarian Tumor Analysis criteria
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Yavuz Emre Sukur
Phone
+905332409381
Email
yesukur@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Sezcan Mumusoglu
Phone
+905326404673
Email
sezcanmumusoglu@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Batuhan Aslan
Organizational Affiliation
Ankara University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Ankara University School of Medicine, Department of Obstetrics and Gynecology
City
Ankara
ZIP/Postal Code
06610
Country
Turkey
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yavuz Emre Şükür, M.D.
Phone
00905332409381
Email
yesukur@gmail.com
First Name & Middle Initial & Last Name & Degree
Batuhan Aslan, M.D.
Phone
00905462555335
Email
drbatuhanaslan@gmail.com

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
3283269
Citation
Akamatsu N, Hirai T, Masaoka H, Sekiba K, Fujita T. [Ultrasonically guided puncture of endometrial cysts--aspiration of contents and infusion of ethanol]. Nihon Sanka Fujinka Gakkai Zasshi. 1988 Feb;40(2):187-91. Japanese.
Results Reference
background
PubMed Identifier
17433319
Citation
Alborzi S, Ravanbakhsh R, Parsanezhad ME, Alborzi M, Alborzi S, Dehbashi S. A comparison of follicular response of ovaries to ovulation induction after laparoscopic ovarian cystectomy or fenestration and coagulation versus normal ovaries in patients with endometrioma. Fertil Steril. 2007 Aug;88(2):507-9. doi: 10.1016/j.fertnstert.2006.11.134. Epub 2007 Apr 11.
Results Reference
background
PubMed Identifier
29759886
Citation
Benaglia L, Busnelli A, Biancardi R, Vegetti W, Reschini M, Vercellini P, Somigliana E. Oocyte retrieval difficulties in women with ovarian endometriomas. Reprod Biomed Online. 2018 Jul;37(1):77-84. doi: 10.1016/j.rbmo.2018.03.020. Epub 2018 Apr 13.
Results Reference
background
PubMed Identifier
19502358
Citation
Benaglia L, Somigliana E, Vercellini P, Abbiati A, Ragni G, Fedele L. Endometriotic ovarian cysts negatively affect the rate of spontaneous ovulation. Hum Reprod. 2009 Sep;24(9):2183-6. doi: 10.1093/humrep/dep202. Epub 2009 Jun 5.
Results Reference
background
PubMed Identifier
28579409
Citation
Cohen A, Almog B, Tulandi T. Sclerotherapy in the management of ovarian endometrioma: systematic review and meta-analysis. Fertil Steril. 2017 Jul;108(1):117-124.e5. doi: 10.1016/j.fertnstert.2017.05.015. Epub 2017 Jun 1.
Results Reference
background
PubMed Identifier
24435778
Citation
Dunselman GA, Vermeulen N, Becker C, Calhaz-Jorge C, D'Hooghe T, De Bie B, Heikinheimo O, Horne AW, Kiesel L, Nap A, Prentice A, Saridogan E, Soriano D, Nelen W; European Society of Human Reproduction and Embryology. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014 Mar;29(3):400-12. doi: 10.1093/humrep/det457. Epub 2014 Jan 15.
Results Reference
background
PubMed Identifier
19056774
Citation
Garcia-Velasco JA, Somigliana E. Management of endometriomas in women requiring IVF: to touch or not to touch. Hum Reprod. 2009 Mar;24(3):496-501. doi: 10.1093/humrep/den398. Epub 2008 Dec 4.
Results Reference
background
PubMed Identifier
18425908
Citation
Hart RJ, Hickey M, Maouris P, Buckett W. Excisional surgery versus ablative surgery for ovarian endometriomata. Cochrane Database Syst Rev. 2008 Apr 16;(2):CD004992. doi: 10.1002/14651858.CD004992.pub3.
Results Reference
background
PubMed Identifier
31318420
Citation
Horton J, Sterrenburg M, Lane S, Maheshwari A, Li TC, Cheong Y. Reproductive, obstetric, and perinatal outcomes of women with adenomyosis and endometriosis: a systematic review and meta-analysis. Hum Reprod Update. 2019 Sep 11;25(5):592-632. doi: 10.1093/humupd/dmz012.
Results Reference
background
PubMed Identifier
18684448
Citation
Meuleman C, Vandenabeele B, Fieuws S, Spiessens C, Timmerman D, D'Hooghe T. High prevalence of endometriosis in infertile women with normal ovulation and normospermic partners. Fertil Steril. 2009 Jul;92(1):68-74. doi: 10.1016/j.fertnstert.2008.04.056. Epub 2008 Aug 5.
Results Reference
background
PubMed Identifier
33039127
Citation
Miquel L, Preaubert L, Gnisci A, Netter A, Courbiere B, Agostini A, Pivano A. Transvaginal ethanol sclerotherapy for an endometrioma in 10 steps. Fertil Steril. 2021 Jan;115(1):259-260. doi: 10.1016/j.fertnstert.2020.08.1422. Epub 2020 Oct 8.
Results Reference
background
PubMed Identifier
32986747
Citation
Miquel L, Preaubert L, Gnisci A, Resseguier N, Pivano A, Perrin J, Courbiere B. Endometrioma ethanol sclerotherapy could increase IVF live birth rate in women with moderate-severe endometriosis. PLoS One. 2020 Sep 28;15(9):e0239846. doi: 10.1371/journal.pone.0239846. eCollection 2020.
Results Reference
background
PubMed Identifier
25740883
Citation
Roustan A, Perrin J, Debals-Gonthier M, Paulmyer-Lacroix O, Agostini A, Courbiere B. Surgical diminished ovarian reserve after endometrioma cystectomy versus idiopathic DOR: comparison of in vitro fertilization outcome. Hum Reprod. 2015 Apr;30(4):840-7. doi: 10.1093/humrep/dev029. Epub 2015 Mar 3.
Results Reference
background
PubMed Identifier
29510964
Citation
Rubod C, Jean Dit Gautier E, Yazbeck C. [Surgical management of endometrioma: Different alternatives in term of pain, fertility and recurrence. CNGOF-HAS Endometriosis Guidelines]. Gynecol Obstet Fertil Senol. 2018 Mar;46(3):278-289. doi: 10.1016/j.gofs.2018.02.013. Epub 2018 Mar 3. French.
Results Reference
background
PubMed Identifier
25750209
Citation
Somigliana E, Benaglia L, Paffoni A, Busnelli A, Vigano P, Vercellini P. Risks of conservative management in women with ovarian endometriomas undergoing IVF. Hum Reprod Update. 2015 Jul-Aug;21(4):486-99. doi: 10.1093/humupd/dmv012. Epub 2015 Mar 6.
Results Reference
background
PubMed Identifier
32496142
Citation
Sukur YE, Ozmen B, Yakistiran B, Atabekoglu CS, Berker B, Aytac R, Sonmezer M. Endometrioma surgery is associated with increased risk of subsequent assisted reproductive technology cycle cancellation; a retrospective cohort study. J Obstet Gynaecol. 2021 Feb;41(2):259-262. doi: 10.1080/01443615.2020.1754366. Epub 2020 Jun 4.
Results Reference
background
PubMed Identifier
19573300
Citation
Yazbeck C, Madelenat P, Ayel JP, Jacquesson L, Bontoux LM, Solal P, Hazout A. Ethanol sclerotherapy: a treatment option for ovarian endometriomas before ovarian stimulation. Reprod Biomed Online. 2009 Jul;19(1):121-5. doi: 10.1016/s1472-6483(10)60055-7.
Results Reference
background
PubMed Identifier
22959083
Citation
Yazbeck C, Koskas M, Cohen Scali S, Kahn V, Luton D, Madelenat P. [How I do... ethanol sclerotherapy for ovarian endometriomas]. Gynecol Obstet Fertil. 2012 Oct;40(10):620-2. doi: 10.1016/j.gyobfe.2012.07.029. Epub 2012 Sep 5. No abstract available. French.
Results Reference
background

Learn more about this trial

Ethanol Sclerotherapy Prior to ART

We'll reach out to this number within 24 hrs